MRC1 and neuroblastoma: This effect of anti-PD1 therapy against the immunogenic but low MHC class I-expressing idMMR tumors shows that inducing MMR deficiency would not universally sensitize tumors to ICBs, particularly low TMB and immune-cold neuroblastoma tumors.